Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib

Leukemia

Volumn 27, Issue 10, 2013, Pages 2075-2077

  Stessman, H A F ^a   Mansoor, A ^a   Zhan, F ^b,c   Janz, S ^d   Linden, M A ^e   Baughn, L B ^a,e   Van Ness, B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Div Hematol Oncol Blood M   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; THALIDOMIDE;

BONE MARROW; CANCER SURVIVAL; CELL LINE; CELL MATURATION; CELL MIGRATION; CELL POPULATION; DRUG MEGADOSE; EXPERIMENTAL MODEL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LETTER; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MICE; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; RECEPTORS, CXCR4; SARCOMA, MYELOID; SURVIVAL RATE;

EID: 84885595409     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.148     Document Type: Letter

References (14)

1. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
2. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009; 23: 1964-1979.
3. Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther 2013, e-pub ahead of print 27 March 2013; doi:10.1158/1535-7163.MCT-12-1151.
4. Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004; 113: 1763-1773.
5. Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS et al. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res 2007; 67: 4069-4078.
6. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708-2717.
7. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177-3188.
8. Shaughnessy Jr. JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood 2011; 118: 3512-3524.
9. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226-232.
10. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003; 3: 822-829.
11. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
12. Moriuchi M, Ohmachi K, Kojima M, Tsuboi K, Ogawa Y, Nakamura N et al. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses. Tokai J Exp Clin Med 2010; 35: 17-20.
13. Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma 2012; 53: 641-647.
14. Mo SL, Li J, Loh YS, Brown RD, Smith AL, Chen Y et al. Factors influencing the abundance of the side population in a human myeloma cell line. Bone Marrow Res 2011; 2011: 524845.